放疗联合替莫唑胺治疗非小细胞肺癌脑转移瘤的临床观察

doi:10.3760/cma.j.issn.1673-422X.2017.04.007

摘要/Abstract

摘要： 目的探讨放疗联合替莫唑胺治疗非小细胞肺癌（NSCLC）脑转移瘤的临床疗效及不良反应。方法回顾性分析河北大学附属医院放疗科收治的NSCLC脑转移患者51例。按照治疗方法将患者分为实验组（n=26）和对照组（n=25），实验组采用全脑放疗及局部肿瘤缩野加量放疗+口服替莫唑胺，对照组仅采用全脑放疗及局部肿瘤缩野加量放疗，分析两组患者的临床疗效及不良反应。结果治疗后实验组的Karnofsky功能状态评分较对照组改善显著（76.2±6.4∶72.8±5.3），差异有统计学意义（t=2.06，P=0.04），实验组放疗的总有效率高于对照组（80.8%∶64.0%），但是差异无统计学意义（χ2=1.80，P=0.18）。与对照组相比，实验组治疗期间恶心呕吐（80.8%∶28.0%）、骨髓抑制（84.6%∶24.0%）的发生率均明显升高，差异有统计学意义（χ2=14.33，P=0.00；χ2=18.91，P=0.00）；两组患者在头痛（69.2%∶60.1%）、肝肾功能损害（73.1%∶64.0%）方面差异无统计学意义（χ2=0.47，P=0.49；χ2=0.47，P=0.49）。结论放疗联合替莫唑胺治疗NSCLC脑转移能够改善患者生命质量，且不良反应可控，患者可耐受。

关键词: 癌非小细胞肺, 放射疗法, 肿瘤转移, 替莫唑胺

Abstract: Objective To investigate the recent curative effect and adverse reactions of radiotherapy combined with temozolomide in non-small cell lung cancer (NSCLC) patients with brain metastases. Methods The clinical date of 51 NSCLC patients with brain metastases were retrospective analyzed in Department of Radiation Oncology of Affiliated Hospital of Hebei University. Patients were divided into experimental group (n=26) and control group (n=25) according to the different treatment methods. The experimental group underwent whole brain and local tumor radiotherapy plus temozolomide. The control group only received whole brain and local tumor radiotherapy. The recent curative effect and adverse reactions of the two groups were analyzed. Results The Karnofsky performance status score of patients in the experimental group was obviously improved than that in the control group (76.2±6.4 vs. 72.8±5.3), with a significant difference (t=2.06, P=0.04). The total effective rate in the experimental group was higher than that in the control group (80.8% vs. 64.0%), but there was no statistically significant difference (χ2=1.80, P=0.18). Compared with the control group, the incidences of nausea and vomiting (80.8% vs. 28.0%) and bone marrow suppression (84.6% vs. 24.0%) in the experimental group were significantly higher, with significant differences (χ2=14.33, P=0.00; χ2=18.91, P=0.00). There were similar incidences of headache (69.2% vs. 60.1%), liver and kidney damage (73.1% vs. 64.0%) in the two groups, with no significant differences (χ2=0.47, P=0.49; χ2=0.47, P=0.49). Conclusion Radiotherapy combined with temozolomide can improve the quality of life in NSCLC patients with brain metastases, which has controllable and tolerable adverse reactions.

Key words: Carcinoma non-small-cell lung, Radiotherapy, Neoplasm metastases, Temozolomide

滕菲,崔桂敏,史鸿云,刘妙玲,李延红. 放疗联合替莫唑胺治疗非小细胞肺癌脑转移瘤的临床观察[J]. 国际肿瘤学杂志, 2017, 44(4): 271-273.

Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases[J]. Journal of International Oncology, 2017, 44(4): 271-273.

参考文献

［1］ Robins HI, O′Neill A, Mehta M, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT SRS with temozolomide or erlotinib for nonsmall cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto et al［J］. Int J Radiat Oncol Biol Phys, 2013, 86(5): 809-810. DOI: 10.1016/j.ijrobp.2013.03.040. ［2］ Hassler MR, Pfeifer W, KnockeAbulesz TH, et al. Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of nonsmallcell lung cancer: a multicentric Austrian phase Ⅱ study［J］. Wien Klin Wochenschr, 2013, 125(15-16): 481-486. DOI: 10.1007/s00508-013-0402-7. ［3］ Tatar Z, Thivat E, Planchat E, et al. Temozolomide and unusual indications: review of literature［J］. Cancer Treat Rev, 2013, 39(2): 125-135. DOI: 10.1016/j.ctrv.2012.06.002. ［4］ Zou Y, Wang Q, Li B, et al. Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in glioma［J］. Mol Med Rep, 2014, 10(1): 411-416. DOI: 10.3892/mmr.2014.2151. ［5］张胜, 曹远东, 孙新臣, 等. 老年Ⅰ期非小细胞肺癌立体定向放疗疗效观察［J］. 东南大学学报: 医学版, 2013, 32(1): 67-70. DOI: 10.3969/j.issn.1671-6264.2013.01.016. ［6］康勋, 李珊, 谢铮铮, 等. 恶性脑胶质瘤同步放化疗中替莫唑胺化疗的不良反应及对策［J］. 首都医科大学学报, 2012, 33(5): 589-593. DOI: 10.3969/j.issn.1006-7795.2012.05.007. ［7］覃莉, 黄海欣, 陈海辉, 等. 替莫唑胺联合干扰素治疗晚期黑色素瘤的临床研究［J］. 肿瘤药学, 2013, 3(3): 196-199. DOI: 10.3969/j.issn.2095-1264.2013.047. ［8］印海林, 吴伟莉, 金风, 等. 调强放射治疗联合同步及辅助替莫唑胺化疗治疗脑胶质瘤术后残余病灶的临床研究［J］. 肿瘤, 2011, 31(5): 428-430. DOI: 10.3781/j.issn.10007431.2011.05.009. ［9］ Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted lowdose and wholebrain radiotherapy for nonsmallcell lung cancer and breast cancer patients with brain metastases［J］. Cancer, 2008, 113(9): 2524-2531. DOI: 10.1002/cncr.23859. ［10］邬德东, 杨芬, 姚定珠. 替莫唑胺联合放疗治疗非小细胞肺癌脑转移的疗效观察［J］. 现代肿瘤医学, 2013, 21(9): 1997-1999. DOI: 10.3969/j.issn.1672-4992.2013.09.27.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[6]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[7]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[8]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[9]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[12]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[13]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[14]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[15]	马培晗, 张灵敏, 路宁, 张明鑫. 麻醉对肝细胞癌复发转移的影响[J]. 国际肿瘤学杂志, 2023, 50(2): 117-121.